European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms

Figure 11 The clinical features of four JAK2^V617F+ essential thrombocythemia and two JAK2^V617F+ polycythemia vera cases refer to the numbering of cases in Figure 10. Case 2: Clinically JAK2^V617F ET 2 (low serum erythropoetin) and a normocellular ET [World Health Organization (WHO)-ET] bone marrow wit pleomorph small and large megakaryocytes and reticulin fibers (RF) grade 1; Case 3 and 4: Clinically JAK2^V617F ET 2 with a trilinear hypercellular PV bone marrow and RF 0 in case 3: ET 2 with increased cellularity due to increased erythropoiesis RF grade 0 in case 4; Case 5: Clinically JAK2^V617F ET with moderate splenomegaly and a hypercellular megakaryocytic granulocytic myeloproliferation (ET.MGM = ET 3), with dysmorphic megakaryocytes (not cloud-like) and RF grade 0 in case 5; Case 6: Clinically JAK2^V617F ET 2 with a trilinear PV bone marrow picture1 and RF grade 0; Case 7: Clinically JAK2^V617F PV with a 65% hypercellular ET/PV bone marrow picture in between “normocellular ET” (WHO-ET) and trilinear hypercellular (90%-100%) PV picture in case 7 and 8 with PV with increased RCM and erythrocytes above 6 × 10¹²/L. In 2007, we concluded that bone histology alone does not differentiate between JAK2 mutated ET and PV, as compared to control, morphology of pleiomorph megakaryocytes in JAK2^V617F mutated ET and PV are similar Source Poster P-0025. Fourth International Congress on myeloproliferaive disease/myelodysplatic syndrome New York, 2007. ET: Essential thrombocythemia; PV: Polycythemia vera.